Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for XARELTO
- Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
- VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
- Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
- Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
- Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Aneurysms After Kawasaki Disease
- To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
- Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
- Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
- Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
- COVID-19 Antithrombotic Rivaroxaban Evaluation
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions
- Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
- Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
- A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
- Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
- DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
- Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
- Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
- DUAL Antithrombotic Therapy in Patients With AF and ACS
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- DOAC Versus VKA After Cardiac Surgery
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
- Efficacy Comparison of Warfarin Versus Rivaroxaban CVT
- Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
- Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
- Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.
- Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
- Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
- Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
- Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
- Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
- Study of Rivaroxaban for CeREbral Venous Thrombosis
- Start or STop Anticoagulants Randomised Trial (SoSTART)
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
- Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)
- Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
- Rivaroxaban for Patients With Antiphospholipid Syndrome
- Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study
- Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
- RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
- Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study
- Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
- Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
- Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
- Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
- Pleotropic Effect of New Oral Anticoagulants
- XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
- Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity
- Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study
- The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis
- Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty
- Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program
- PROphylaxis in NOn Major Orthopaedic Surgery
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
- Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
- A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
- A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
- Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
- Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
- Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
- Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
- Rivaroxaban in Thrombotic Antiphospholipid Syndrome
- Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
- Rivaroxaban for Antiphospholipid Antibody Syndrome
- A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
- BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
- The Effect of Rivaroxaban in Sickle Cell Disease
- Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
- Evaluation of Wound Drainage After Knee or Hip Arthroplasty
- Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
- Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
- Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study
- A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
- Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
- Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)
- Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
- Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
- Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
- A Prospective Pharmacodynamic Study of Rivaroxaban
- Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)
- Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
- Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy
- Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
- Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
- Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
- Xarelto [SPAF] Post-marketing Surveillance in Japan
- Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)
- Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
- Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
- Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
- Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
- Xarelto Regulatory Post-Marketing Surveillance
- Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
Clinical trials list
click for details